{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:50:09Z","timestamp":1794027009909,"version":"4.8.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non\u2013small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of durvalumab immunotherapy plus concurrent radiotherapy followed by maintenance with durvalumab therapy for treatment of locally advanced NSCLC without chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The multicenter, single-arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized controlled trial was performed by 12 institutions in Japan from September 13, 2019, to May 31, 2022. Participants in the primary registration phase included 74 patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to October 31, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients received radiotherapy (60 Gy) in combination with concurrent and maintenance durvalumab immunotherapy, 10 mg\/kg every 2 weeks, for up to 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point of the rate of 12-month progression-free survival (PFS), as assessed by an independent central review, was estimated using the Kaplan-Meier method and evaluated with 90% CIs calculated using the Greenwood formula. The key secondary end points were PFS, objective response rate, treatment completion rate, and AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data from 35 patients (median [range] age, 72 [44\u201383] years; 31 [88.6%] men) were included in the full analysis set of the evaluable population. The 12-month PFS rate was 72.1% (90% CI, 59.1%-85.1%), and the median PFS was 25.6 months (95% CI, 13.1 months to not estimable) at a median follow-up of 22.8 months (range, 4.3-31.8 months). Scheduled radiation therapy was completed in 97.1% of patients. The confirmed objective response rate was 90.9% (95% CI, 75.7%-98.1%), and the treatment completion rate was 57.6% (95% CI, 39.2%-74.5%). Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of grades 3 or 4 in 4 patients (11.8%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Findings from this phase 2 nonrandomized controlled trial indicate that durvalumab immunotherapy combined with curative radiotherapy for patients with PD-L1\u2013positive, unresectable, locally advanced NSCLC is a promising treatment with tolerable AEs and is appropriate as a study treatment for phase 3 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      Japan Registry of Clinical Trials ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=jRCT2080224763\">jRCT2080224763<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.3309","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T11:32:36Z","timestamp":1694086356000},"page":"1505","source":"Crossref","is-referenced-by-count":77,"title":["Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Motoko","family":"Tachihara","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Tsujino","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Teraoka","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Daga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Internal Medicine III, Wakayama Medical University, Wakayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University, Osakasayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"West Japan Oncology Group (WJOG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi230043r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"coi230043r3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer.","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"coi230043r4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jamaoncol.2021.0113","article-title":"Effect of second-generation vs third-generation chemotherapy regimens with thoracic radiotherapy on unresectable stage III non\u2013small-cell lung cancer: 10-year follow-up of a WJTOG0105 phase 3 randomized clinical trial.","volume":"7","author":"Zenke","year":"2021","journal-title":"JAMA Oncol"},{"issue":"20","key":"coi230043r5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer.","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"coi230043r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100251","article-title":"Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage III NSCLC: safety and efficacy.","volume":"2","author":"Lau","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"coi230043r7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non\u2013small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON).","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"issue":"9","key":"coi230043r8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non\u2013small-cell lung cancer.","volume":"34","author":"Senan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi230043r9","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","article-title":"Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non\u2013small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230043r10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"issue":"19","key":"coi230043r11","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"issue":"19","key":"coi230043r12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non\u2013small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10183","key":"coi230043r13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non\u2013small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"coi230043r14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC.","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"coi230043r15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"coi230043r17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer.","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"coi230043r18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30391-X"},{"issue":"2","key":"coi230043r19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non\u2013small cell lung cancer.","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res"},{"issue":"7","key":"coi230043r20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non\u2013small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi230043r21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","article-title":"Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"coi230043r22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC.","volume":"15","author":"Lin","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"6","key":"coi230043r23","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1001\/jamaoncol.2019.6731","article-title":"Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non\u2013small cell lung cancer: a nonrandomized controlled trial.","volume":"6","author":"Jabbour","year":"2020","journal-title":"JAMA Oncol"},{"key":"coi230043r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.024"},{"key":"coi230043r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6731"},{"key":"coi230043r26","doi-asserted-by":"publisher","year":"2019","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8573"},{"issue":"29","key":"coi230043r27","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non\u2013small-cell lung cancer.","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"key":"coi230043r16"},{"key":"coi230043r2","unstructured":"National Cancer Institute Surveillance, Epidemiology and End Results Program. SEER cancer statistics review (CRS) 1975-2016. Updated April 9, 2020. Accessed July 14, 2023. (https:\/\/seer.cancer.gov\/csr\/1975_2016\/."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2809271\/jamaoncology_tachihara_2023_oi_230043_1699901601.44948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T11:06:30Z","timestamp":1700132790000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2809271"}},"subtitle":["The DOLPHIN Phase 2 Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3309","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}